NCT00201123 is a Phase 2 clinical trial of Aerosol Interferon-Gamma in Tuberculosis, sponsored by NYU Langone Health.

Who is sponsoring NCT00201123?

NCT00201123 is sponsored by NYU Langone Health.

What drugs are being tested in NCT00201123?

Interventions in NCT00201123: Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo.

What condition does NCT00201123 study?

NCT00201123 studies Tuberculosis, AIDS-related Complex.

Is NCT00201123 still recruiting?

NCT00201123 is currently completed. Last updated 14 December 2016.

Are results published for NCT00201123?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-12-14 · How we verify

NCT00201123

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Host Response to Tuberculosis and Acquired Immune Deficiency Syndrome

Completed Phase 2 Results posted Last updated 14 December 2016

What this trial tests

Phase 2 trial testing Aerosol Interferon-Gamma in Tuberculosis in 89 participants. Completed in 1 August 2007.

Timeline

1 April 2005

Primary endpoint
1 January 2007

1 August 2007

Quick facts

Lead sponsor	NYU Langone Health
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	89
Start date	1 April 2005
Primary completion	1 January 2007
Estimated completion	1 August 2007
Sites	2 locations across United States, South Africa

Drugs / interventions tested

Aerosol Interferon-Gamma — full drug profile →
Subcutaneous interferon-gamma — full drug profile →
Placebo

Conditions studied

Tuberculosis — all drugs for Tuberculosis →
AIDS-related Complex — all drugs for AIDS-related Complex →

Sponsor

NYU Langone Health — full company profile →

Who can join

Adults 18 to 75, any sex, with Tuberculosis or AIDS-related Complex. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sputum Conversion
Time frame: Measured at 16 Weeks

Sponsor's own description

This study will evaluate the lung's immune response to mycobacterium tuberculosis (Mtb) infection and will modulate that response with interferon-gamma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis.
Dawson R, Condos R, Tse D, Huie ML, et al · · 2009 · cited 86× · PMID 19753300 · DOI 10.1371/journal.pone.0006984
Interferon therapy and its association with depressive disorders - A review.
Lai JY, Ho JX, Kow ASF, Liang G, et al · · 2023 · cited 28× · PMID 36911685 · DOI 10.3389/fimmu.2023.1048592

Verify or expand the search:

Other recruiting trials for Tuberculosis

Currently open trials in the same condition.

NCT05917210 — Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda · NA · recruiting
NCT07170735 — Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level · recruiting
NCT07484490 — Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis · NA · recruiting
NCT06318416 — Precision Rifampin Trial for Personalized Dosing · Phase 1 · recruiting
NCT07170800 — A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets · Phase 2 · recruiting

Other NYU Langone Health trials

Trials by the same sponsor.

NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00201123 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
Last refreshed: 14 December 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00201123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing